Inizio Biotech.
Personalized solutions curated to maximize asset value at every opportunity.
Maximize value creation.
With our connected suite of capabilities, we deliver best-in-class biotech services to clients. Our empowered experts bring deep expertise across therapeutic areas, helping to mitigate risks and maximize value at every stage.
From clinical development to commercialization.
At the right time in the journey.
We appreciate that sometimes you will need us more, and sometimes less, so we personalize our solutions to scale up or down, just as you need us. Always bringing you a value creation mindset to help maximize every opportunity.
Phase II
Maximize the value of your asset at phase II clinical milestones.
Personalized and dedicated services coordinated by a single strategic point of contact.
We bring you personalized and dedicated services exactly when you need them because we understand that every day is a value creation opportunity. Our integrated biotech solutions are coordinated by a single strategic point of contact, who understands your business, bringing efficiencies and ensuring connectivity in the services provided.
Get to know our leadership team.
Navigate this carousel with the arrows.
Dean McAlister
Executive Vice President, Inizio BiotechAs EVP for Global Biotech Enterprise Solutions, Dean spearheads business development for Inizio efforts across our business units and agencies focused on emerging biotech organizations. Prior to this role commencing 1/1/22, Dean worked 5 years at STEM Healthcare, growing US business development and then as North America President. Before joining the healthcare services sector, Dean had an entire career at AstraZeneca, progressing through 16 roles with increasing responsibility in Sales, Training, Market Research, Marketing, Market Access, and US Executive Leadership.
Colin Stanley
Global President,Inizio Advisory
Serving as Advisory's Global President since September 2019, Colin Stanley has extensive experience in Senior Executive roles. He has been responsible for a business unit of 3,000 employees globally, providing strategic resourcing and functional services. He also held a number of roles during his 20-year career at ICON, including Chief Operating Officer of DOCS and Vice President of Clinical Operations in Asia.
Greg Flynn
Global President,Inizio Engage
Joining Ashfield in 2005 as a Regional Account Director in the UK, Greg has since worked with our teams across the UK, Japan and the US. He established and ran our joint venture in Japan before moving to the US in 2017 to lead Engage before his appointment as President of Engage in September 2019.
Reid Connolly
Global President, Inizio EvokeCEO, Evoke
As CEO & Founder of Evoke, Reid leads the organization globally. Reid founded Evoke in 2006 in pursuit of a simple yet powerful idea—to make health more human™. This idea caught fire with like-minded clients who were hungry for rich, insight-driven strategies that drive real change for brands and people.
Elaine Ferguson
Global President,Inizio Medical
Joining Medistrava in 2015, Elaine helped double the size of the organization through organic growth and acquisition to create a fully integrated medical, health economics and market access platform. Now, she joins us as President of Inizio Medical. As a trained neuropsychologist, Elaine has enjoyed a career in research and clinical practice before joining the industry, combining her background in science and behavior to drive evidence-based strategies that apply to real-world healthcare challenges.
Sharing our expertise is what we do.
We work in partnership with over 100 Biotech companies across the globe. We share our expertise from over 650 PhD’s, blending the science and commercial insight to guide, validate, and inspire the decisions that matter most.
-
Read more
The phase II inflection point: Investing to maximize asset value
Harness the collective expertise of our biotech experts to maximize the value of your asset across every step of your journey to commercialization.
-
Read more
Inizio Biotech key takeaways from JPM industry event
J.P. Morgan recently held its 42nd annual healthcare conference in San Francisco, bringing together tens of thousands...
-
Read more
The role of AI in a data-centric approach to biotech commercialization
Emerging biotechs are increasingly recognizing the significance of data in driving innovation and ensuring the success...
-
Read more
Navigating the rocky path to commercial success for biopharma launches
Biopharma organizations and emerging biotechs must contend with a market in constant flux on their journey to product...
Your market-leading commercialization partner.
Leveraging our connected suite of capabilities, our experts will guide you through each pivotal moment in your asset’s lifecycle, creating tailored solutions that simplify the complex, unlock value, and enhance treatment outcomes.